脉络舒通丸联合阿托伐他汀对冠心病PCI术患者血脂、炎症因子及术后再狭窄的影响  

Effects of Mailuoshutong Pill Combined with Atorvastatin on Blood Lipid,Inflammatory Factors and Postoperative Restenosis in Patients with Coronary Heart Disease Undergoing PCI

作　　者：胡文星 赵春容 周玲娟 刘娟珠 孙鑫[3] HU Wen-xing;ZHAO Chun-rong;ZHOU Ling-juan;LIU Juan-zhu;SUNXin(Department of Internal Medicine-Cardiovascular,Hunan Provincial People's Hospital,Changsha,Hunan,410002,China;Second Ward of Internal Medicine-Cardio vascular,Jinan Fifth People's Hospital,Ji'nan,Shandong,250000,China;Department of Critical Care Medicine,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,200032,China)

机构地区：[1]湖南省人民医院心内科,湖南长沙410002 [2]济南市第五人民医院心内二病区,山东济南250000 [3]上海中医药大学附属龙华医院重症医学科,上海200032

出　　处：《现代生物医学进展》2022年第3期519-523,共5页Progress in Modern Biomedicine

基　　金：湖南省卫生厅科研基金项目(C2012-011)。

摘　　要：目的:探讨脉络舒通丸联合阿托伐他汀对冠心病经皮冠状动脉介入(PCI)术患者血脂、炎症因子及术后再狭窄的影响。方法:选择2018年5月~2020年2月期间我院接收的冠心病PCI术患者93例,分为A、B两组,A组(46例)给予阿托伐他汀治疗,B组(47例)给予脉络舒通丸联合阿托伐他汀治疗,比较两组患者临床疗效、心电图疗效、血脂、炎症因子及术后再狭窄发生率。结果:B组治疗2个月后的临床总有效率为93.62%(44/47),高于A组的76.09%(35/46)(P<0.05)。B组治疗2个月后的心电图总有效率为89.36%(42/47),高于A组的67.39%(31/46)(P<0.05)。治疗2个月后两组高密度脂蛋白胆固醇(HDL-C)升高,白介素-6(IL-6)、胆固醇(TC)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)降低(P<0.05),治疗2个月后B组TC、TG、LDL-C、IL-6、CRP、TNF-α低于A组,HDL-C高于A组(P<0.05)。B组术后再狭窄发生率为6.38%(3/47),明显低于A组的23.91%(11/46),差异有统计学意义(P<0.05)。结论:脉络舒通丸联合阿托伐他汀治疗冠心病PCI术患者,疗效满意,可有效改善心电图疗效、血脂、炎症因子水平,并降低术后再狭窄发生率。Objective:To investigate the effects of mailuoshutong pill combined with atorvastatin on blood lipid,inflammatory factors and postoperative restenosis in patients with coronary heart disease undergoing percutaneous coronary intervention(PCI).Methods:93 patients with coronary heart disease undergoing PCI who were received in our hospital from May 2018 to February 2020 were selected,they were divided into two groups as group A,B,group A(n=46)were treated with atorvastatin,group B(n=47)were treated with mailuoshutong pill combined with atorvastatin,the clinical effect,electrocardiogram effect,blood lipid,inflammatory factors and postoperative restenosis rate of patients in the two groups were compared.Results:The total clinical effective rate of group B was93.62%(44/47)after 2 months of treatment,which was higher than 76.09%(35/46)of the group A(P<0.05).The total effective rate of electrocardiogram in group B was 89.36%(42/47)after 2 months of treatment,which was higher than 67.39%(31/46)of the group A(P<0.05).The high-density lipoprotein cholesterol(HDL-C)was increased and Interleukin-6(IL-6),total cholesterol(TC),c-reactive protein(CRP),tumor necrosis factor-α(TNF-α),low density lipoprotein cholesterol(LDL-C),triglyceride(TG)were decreased in the two groups after 2 months of treatment(P<0.05).TC,TG,LDL-C,IL-6,CRP,TNF-αin group B were lower than those of group A,HDL-C in group B was higher than that of group A after 2 months of treatment(P<0.05).The incidence of postoperative restenosis in group B was6.38%(3/47),which was significantly lower than 23.91%(11/46)in group A,the difference was statistically significant P<0.05).Conclusion:Mailuoshutong pill combined with atorvastatin treat the patients with coronary heart disease undergoing PCI,the efficacy is satisfactory,which can effectively improve the electrocardiogram efficacy,blood lipid,inflammatory factor levels,and reduce the incidence of postoperative restenosis.

关 键 词：血脂 经皮冠状动脉介入术 阿托伐他汀 冠心病 脉络舒通丸 炎症因子 

分 类 号：R541.4[医药卫生—心血管疾病]